| Protocol |
Title |
| A5073 |
A Randomized Phase II Open Label Study to Compare Twice Daily Potent
Antiretroviral Therapy With Once Daily Potent Antiretroviral Therapy and to
Compare Self-Administered Therapy and Therapy Administererd Under Direct
Observation |
| A5141 |
Randomized Study to Evaluate Immediate Potent Antiretroviral Therapy
for HIV- Infected Subjects with CD4 Counts Less Than 200 Cells/mm3 Admitted
to Intensive Care Areas with an AIDS -Defining Illness, Pneumonia, or Sepsis |
| A5142 |
A Phase III, Randomized, Open-Label Comparison of Lopinavir/Ritonavir plus
Efavirenz vs. Lopinavir/Ritonavir plus 2 NRTIs vs. Efavirenz plus 2 NRTIs for
the Initial Therapy for HIV-1 Infection |
| A5164 |
Antiretroviral Therapy for HIV-Infected Adults Presenting with Acute
Opportunistic Infections: Immediate versus Delayed Initiation |
| A5165 |
A Phase I/II Randomized, Double-Blind, Placebo-Controlled Pilot Study of
b-D-2,6-Diaminopurine Dioxolane (DAPD) vs. DAPD plus Mycophenolate Mofetil (MMF)
in Treatment Experienced Subjects |
| A5173 |
A Pilot Study to measure the Clearance of Replication-Competent HIV-1 in
Resting Memory CD4+ Cells in HIV Infected Subjects Who Receive T-20 + Oral
Combination Antiretroviral Therapy |
| A001 |
Once Daily Dosing of Lopinavir/Ritonavir (LPV/r, Kaletra) in a Simplified,
Three-Drug Regimen Administered as Directly Observed Therapy (DOT) Versus
Self-Administered Therapy (SAT) in HIV-Infected Subects Who Are Antiretroviral
Treatment Naïve |
![[Company Logo Image]](_borders/umacrulogo1.jpg)
